The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed several categories of patient characteristics (age...

Full description

Bibliographic Details
Main Authors: Josée M. Zijlstra, George Follows, Rene-Olivier Casasnovas, Joost S. P. Vermaat, Nagesh Kalakonda, Sylvain Choquet, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, Miklos Egyed, Fritz Offner, Theodoros P. Vassilakopoulos, Priyanka Samal, Matthew Ku, Jenny Xu, Kelly Corona, Kamal Chamoun, Jatin Shah, Miguel Canales, Marie Maerevoet
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
selinexor
diffuse large B-cell lymphoma
exportin 1
SADAL study
Online Access:https://www.mdpi.com/2072-6694/14/3/791

Internet

https://www.mdpi.com/2072-6694/14/3/791

Similar Items